Granular Therapeutics

Name

Granular Therapeutics

Legal name

Granular Therapeutics

Website

https://granulartherapeutics.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

1–10 employees

Short description

Granular Therapeutics is a privately held UK-based biotechnology subsidiary of Alys Pharmaceuticals that develops granulocyte-targeted therapies for chronic inflammatory diseases, operating as a single-product, early-stage R&D platform with 1–10 employees.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Granulocyte-targeted therapy
• Chronic inflammatory disease therapeutics
• Biopharmaceutical drug development
• Mast cell therapy
• Inflammatory disease research

Headquarters

HQ city

Sandwich

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Core offering

Granular Therapeutics develops a granulocyte-targeted therapeutic platform aimed at treating chronic inflammatory diseases. The company focuses on modulating granulocytes as a novel treatment strategy for inflammatory conditions, operating as a single-product biotechnology firm developing targeted therapies in this disease area.

Differentiator

Problem solved

Functional benefit

Products and services

• Granulocyte-Targeted Therapy Platform

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Alys PharmaceuticalscoreOthersGranular Therapeutics operates as a fully owned subsidiary of Alys Pharmaceuticals, representing a corporate ownership structure where Alys Pharma has full control over the subsidiary's operations and strategic direction in the biopharmaceutical space.

Broad incumbents

• AstraZeneca: AstraZeneca markets Fasenra (benralizumab, anti–IL-5R) and Tezspire (anti-TSLP), both targeting granulocyte/eosinophil pathways in asthma and chronic inflammatory disease. It is a broad incumbent in the same therapeutic space Granular is targeting.
• GSK: GSK markets Nucala (mepolizumab, anti–IL-5), a granulocyte/eosinophil-targeting biologic approved in multiple chronic inflammatory indications. GSK is a broad incumbent competitor in the eosinophil/granulocyte-targeted inflammation space.
• Sanofi: Sanofi (with Regeneron) markets Dupixent (dupilumab), the leading IL-4/IL-13 biologic for atopic and inflammatory disease. While mechanistically distinct, Sanofi is the broad incumbent dominating the chronic inflammation therapeutic space Granular is addressing.
• Novartis: Novartis has a broad inflammation/immunology portfolio (e.g., Cosentyx) and pursues eosinophil and immune-cell-targeted therapies across chronic inflammatory diseases. It is a broad incumbent with overlapping therapeutic ambitions to Granular.

Direct peers

• Blueprint Medicines: Blueprint Medicines markets Ayvakit (avapritinib) for systemic mastocytosis and develops other mast-cell-directed kinase inhibitors, making it a direct peer in the granulocyte/mast-cell-targeted therapeutics space for chronic inflammatory and proliferative mast-cell diseases.
• Allakos: Allakos is a clinical-stage biotechnology company developing antibody-based therapeutics that target mast cells and eosinophils — the same immune cell populations Granular Therapeutics is pursuing. Both companies are pursuing granulocyte/mast-cell-targeted approaches to inflammatory disease, making Allakos a highly comparable direct peer.
• Celldex Therapeutics: Celldex is developing CDX-0159, an anti-KIT antibody that targets mast cells directly — directly comparable to Granular's granulocyte/mast-cell-targeted therapy approach in chronic inflammatory disease. Celldex operates at a similar stage in mast-cell biology with comparable modality.
• Escient Pharmaceuticals: Escient is developing MRGPRX2 antagonists and other targeted therapies for mast cell-mediated diseases such as chronic spontaneous urticaria. It is an emerging direct peer to Granular in mast-cell-targeted inflammatory therapeutics.

Emerging players

• Cogent Biosciences: Cogent Biosciences is developing bezuclastinib, a kinase inhibitor being studied in mast cell-driven conditions including systemic mastocytosis and chronic spontaneous urticaria. It is an emerging player with partial overlap to Granular's granulocyte/mast-cell therapeutic focus.

Others

• Alys Pharmaceuticals: Alys Pharmaceuticals is Granular Therapeutics' parent company and operates in the inflammation biopharmaceutical space. Although not a market competitor, it is the strategic entity funding and directing Granular's granulocyte-targeted development program.

Market position

Customer concentration

• LinkedInlinkedin.com/company/granular-therapeutics-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Granular Therapeutics